Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Gastrointestinal cancer

Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA

Nature Reviews Clinical Oncology volume 22, page 623 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

Trastuzumab plus platinum–fluoropyrimidine chemotherapy has been the backbone of frontline therapy for advanced-stage HER2-positive gastroesophageal adenocarcinoma (HER2+ GEA) since 2010 on the basis of results from the landmark phase III ToGA trial. Now, data from a phase II trial indicate that zanidatamab, a biparatopic antibody targeting two distinct epitopes of HER2, might improve outcomes in this setting.

In this single-arm trial, patients with previously untreated advanced-stage HER2+ GEA received zanidatamab in combination with either 5-fluorouracil, folinic acid and oxaliplatin (n = 24), capecitabine and oxaliplatin (n = 20), or 5-fluorouracil and cisplatin (n = 2). The primary end point was confirmed objective response rate (ORR).

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA. Nat Rev Clin Oncol 22, 623 (2025). https://doi.org/10.1038/s41571-025-01048-4

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-025-01048-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing